Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Zippelius

Showing results (51-60 of 163) with videos related to

Pageof 17
Sort By:
Cancer Medicine|April 21, 2023
Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entitiesTarun Mehra, Kanchan Dongre, Maria Boesing, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapyViktor H Koelzer, Tobias Buser, Niels Willi, et al.
International Journal of Cancer|February 13, 2007
NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltrationJean-Philippe Theurillat, Fabienne Ingold, Claudia Frei, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2020
PD-1<sup>+</sup> natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockadeMarcel P Trefny, Monika Kaiser, Michal A Stanczak, et al.
Swiss Medical Weekly|May 20, 2019
Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort StudyEmanuel Lengwiler, Susanne Stampf, Alfred Zippelius, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|March 17, 2015
Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activityNarasimha Rao Uda, Volker Seibert, Frank Stenner-Liewen, et al.
Oncoimmunology|January 9, 2018
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitorsHeinz Läubli, Viktor H Koelzer, Matthias S Matter, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyViktor H Koelzer, Sacha I Rothschild, Deborah Zihler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1Maha Ayyoub, Alfred Zippelius, Mikaël J Pittet, et al.
Pageof 17

Showing results (51-60 of 163) with videos related to

Sort By:
Pageof 17
Cancer Medicine|April 21, 2023
Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entitiesTarun Mehra, Kanchan Dongre, Maria Boesing, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapyViktor H Koelzer, Tobias Buser, Niels Willi, et al.
International Journal of Cancer|February 13, 2007
NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltrationJean-Philippe Theurillat, Fabienne Ingold, Claudia Frei, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2020
PD-1<sup>+</sup> natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockadeMarcel P Trefny, Monika Kaiser, Michal A Stanczak, et al.
Swiss Medical Weekly|May 20, 2019
Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort StudyEmanuel Lengwiler, Susanne Stampf, Alfred Zippelius, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|March 17, 2015
Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activityNarasimha Rao Uda, Volker Seibert, Frank Stenner-Liewen, et al.
Oncoimmunology|January 9, 2018
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitorsHeinz Läubli, Viktor H Koelzer, Matthias S Matter, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyViktor H Koelzer, Sacha I Rothschild, Deborah Zihler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1Maha Ayyoub, Alfred Zippelius, Mikaël J Pittet, et al.
Pageof 17